Unlike their large pharmaceutical counterparts, midsize pharmaceutical companies are usually not constrained by huge overheads or layers of bureaucracy. What these companies do have is a more narrow business focus, which allows them to concentrate on specific areas of drug development. That, in turn, allows them to focus mostly on diseases too small for their bigger rivals to target.
Several years ago, some analysts believed that many midsize pharma companies would fall prey to the M&A frenzy, but instead they are proving that they can compete not only in the United States but globally as well.
Being smaller also allows these companies to be a bit more scientifically innovative. Additionally, midsize pharmaceutical executives say their salespeople have an easier time building relationships with doctors, since they sell only to a few specialists and not to general practitioners…
Jeffrey Aronin. President and CEO, Ovation Pharmaceuticals Inc., Deerfield, Ill.; Ovation is a fully integrated global pharmaceutical company with one purpose: advancing medicines by developing, manufacturing, and marketing medically necessary branded pharmaceutical products that satisfy unmet medical needs in the areas of CNS, hematology/oncology, and hospital products. For more information, visit ovationpharma.com.
Geert Cauwenbergh. CEO and Founder, Barrier Therapeutics Inc., Princeton, N.J.; Barrier Therapeutics is a pharmaceutical company focused on developing and commercializing products in the field of dermatology and is committed to developing innovative products that address major medical needs in the treatment of dermatological diseases and disorders of the skin. For more information, visit barriertherapeutics.com.
Lonnel Coats. President and Chief Operating Officer, Eisai Inc., Teaneck, N.J.; Eisai is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., which was established in 1995 and began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. For more information, visit eisai.com.
Marc Giroux. CEO, Kurve Technology Inc., Bothell, Wash.; Kurve Technology designs and develops nasal drug-delivery systems for local, systemic, and nose-to-brain medical therapies. For more information, visit kurvetech.com.
A.J. Kazimi. Founder and CEO, Cumberland Pharmaceuticals Inc., Nashville, Tenn.; Cumberland is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. For more information, visit cumberlandpharma.com.
Warren Levy, Ph.D. President and CEO, Unigene Laboratories Inc., Fairfield, N.J.; Unigene leverages the broad utility of its patented manufacturing and delivery technologies to create a new generation of safe and effective peptide pharmaceuticals that can provide a more natural approach to the prevention and treatment of disease. For more information, visit unigene.com.
Philip S. Tabbiner. President and CEO, Zylera Pharmaceuticals, Chapel Hill, N.C.; Zylera is a specialty pharmaceutical company focused on developing medications that will treat multiple diseases arising within the inflammation and immunosuppressive pathways. For more information, visit zylera.com.
Hiromi Yoshikawa. Chairman and CEO, Otsuka America Pharmaceutical Inc., Rockville, Md.; Otsuka America is a fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular, and gastrointestinal therapeutic treatments. For more information, visit otsuka.com.